Evolocumab, a monoclonal antibody, represents a significant advancement in the treatment of hyperlipidemia, particularly in managing elevated low-density lipoprotein cholesterol (LDL-C) levels. Marketed under the brand name Repatha by Amgen, Evolocumab has garnered substantial attention due to its efficacy in reducing LDL-C levels, a critical factor in cardiovascular disease (CVD) management....
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian